Stents

This channel includes news and new technology innovations for stents, also called vascular scaffolds. Stents are used to help prop open a vessel treated by balloon angioplasty because of the barotrauma caused by the extreme stretching of vessel walls. The stent enables to vessel to heal in an open position with collapsing. Drug eluting stents (DES) are coated in anti-proliferative drugs to precent scar tissue growth which can cause restenosis and occlude the vessel. DES require antiplatelet therapy because the drug carrier polymer on DES can cause thrombus inside the stent, even years after treatment, which is why bare metal stents are still used in some patients. This page includes news on coronary stents, carotid stents, peripheral stents, bioresorbable stents, and renal stents. 

News

October 14, 2009 – Medtronic Inc. yesterday initiated a feasibility study of an interventional treatment for ...

Home October 14, 2009
Home
News

October 6, 2009 – The Harvard Clinical Research Institute (HCRI) said last week the first patients are enrolled ...

Home October 06, 2009
Home
News

October 6, 2009 - Boston Scientific Corp. announced it has received 510(k) clearance from the U.S. Food and Drug ...

Home October 06, 2009
Home
News

October 6, 2009 – Boston Scientific Corp. released data during TCT 2009 from the TAXUS ATLAS clinical program, a ...

Home October 06, 2009
Home
News

October 5, 2009 – In a breakthrough development that could dramatically reduce the number of leg amputations and ...

Home October 10, 2011
Home
News

October 1, 2009 – Flexible Stenting Solutions Inc. (FSS) said this week it received conditional investigational ...

Home October 01, 2009
Home
News

October 1, 2009 – The six-month clinical outcome of Sahajanand Medical Technologies Supralimus Sirolimus-Eluting ...

Home October 01, 2009
Home
News

September 30, 2009 – Invatec this week at the European CIRSE 2009 conference launched its latest self-expanding ...

Home September 30, 2009
Home
News

September 30, 2009 – New clinical data released at TCT 2009 last week showed strong and sustained efficacy and ...

Home September 30, 2009
Home
bbott's XIENCE V Everolimus-Eluting Coronary Stent achieved superiority in the key safety and efficacy measures compared to the TAXUS Express Paclitaxel-Eluting Coronary Stent at one year in SPIRIT IV Trial.
Feature | Stents | Dave Fornell

September 29, 2009 – Among the biggest news to come out of TCT 2009 last week was the late-breaking data from the ...

Home September 30, 2009
Home
News

September 29, 2009 – Cordis Corp. and Boston Scientific announced late today they reached an agreement to resolve ...

Home September 29, 2009
Home
News

September 29, 2009 – Elixir Medical Corp. last week at TCT 2009 announced positive results from three multicenter ...

Home September 29, 2009
Home
News

September 29, 2009 – Boston Scientific Corp. Sept. 25 announced two-year follow-up data from the HORIZONS-AMI ...

Home September 29, 2009
Home
News

September 29, 2009 – At six months, patients receiving the NEVO Sirolimus-Eluting Coronary Stent reported ...

Home September 29, 2009
Home
News

September 21, 2009 — Boston Scientific Corp. today welcomed three-year results from the SPIRIT III clinical trial ...

Home September 22, 2009
Home
Subscribe Now